Sandostatin for Control of GH, IGF-1, Gastrointestinal HormoneSandostatin LAR Information
Sandostatin LAR Octreotide IM Injection






Search
 
About Sandostatin®  
 

Sandostatin® LAR® (octreotide/IM injection) is the most prescribed1 and most studied2 medical therapy in the treatment of acromegaly and symptoms of gastro-entero-pancreatic neuroendocrine (GEP NE) tumours. Sandostatin® LAR® maintains all of the clinical and pharmacological characteristics of the immediate-release dosage form of subcutaneous (SC) Sandostatin® (octreotide acetate) Injection, with the added feature of convenient, once-monthly administration. Sandostatin® LAR® has a well-tolerated safety profile backed by more than a decade of clinical use.

Sandostatin for Acromegaly and GEP NE Tumours
Source: Novartis Pharma AG

  
  Basic Information

In the majority of patients, Acromegaly Sandostatin® LAR® controls growth hormone (GH) and insulin-like growth factor I (IGF-I) and reduces the size of tumours to help control symptoms of acromegaly.

GEP NE tumours
In the majority of patients, Sandostatin® LAR® controls gastrointestinal hormone secretion to help reduce diarrhoea and flushing and suppress 5- hydroxyindoleacetic acid (5-HIAA) in patients with GEP NE tumours and carcinoid syndrome.

Click here for more information about Sandostatin® LAR®
Administering Sandostatin® LAR®

The unique, slow-release-dosage formulation of Sandostatin® LAR® allows for once-monthly administration, and a new pre-filled vehicle syringe and redesigned needle size make mixing and administering easier. Visit this section for dosage, preparation and injection instructions for Sandostatin® LAR®.
History of Sandostatin® LAR®
Sandostatin® LAR® is the most published3, most prescribed4 somatostatin analogue. Learn more about the development of Sandostatin® LAR® and its unparalleled efficacy in treating symptoms of acromegaly and symptoms of GEP NE tumours.
 
Learn More
Novartis Core Labeling Text
FAQ
Mechanism of Action for Acromegaly
View a video on the Sandostatin LAR Mechanism of Action for Acromegaly.
View the video

Mechanism of Action for GEP NE Tumours
View a video on the Sandostatin LAR Mechanism of Action for GEP NE Tumours.
View the video

1 Scott-Levin's Physician Drug & Diagnosis Audit (PDDA) from Verispan, September 1996-August 2002.
2 PubMed [database online]. National Center for Biotechnology Information. Available at: www.ncbi.nih.gov/gquery/gquery.fcgi?CMD. Accessed May 2003.
3 PubMed [database online]. National Center for Biotechnology Information. Available at: www.ncbi.nih.gov/gquery/gquery.fcgi?CMD. Accessed May 2003.
4 IMS Report to Novartis Pharma AG, 2002.